Roche Holding stock builds on earnings and pipeline strength

Roche Holding stock reflects a 2025 base that still matters for 2026: CHF 60.5 billion in sales and CHF 11.1 billion in core operating profit, with full-year 2025 core EPS at CHF 18.85.

Roche Holding AG (ISIN CH0012032048) enters 2026 with a 2025 revenue base of CHF 60.5 billion and core operating profit of CHF 11.1 billion, while core earnings per share reached CHF 18.85 for the year. Those figures frame Roche Holding stock as a company whose valuation still depends on execution across pharma and diagnostics rather than on a single headline catalyst.

CHF 60.5 billion sales base

Roche reported 2025 sales of CHF 60.5 billion, down 2% at constant exchange rates, while the company also said core operating profit increased 7% to CHF 11.1 billion and core EPS rose 7% to CHF 18.85. The combination matters because sales weakness and profit growth came from different parts of the group, which usually pushes investors to look closely at mix and margin rather than only top-line growth.

That 7% rise in core operating profit versus the prior year is the cleanest quantified comparison in the latest annual data, and it gives Roche more room to defend its earnings profile even when currency effects and portfolio shifts complicate reported growth. For Roche Holding stock, the main question is whether that profit conversion can be sustained into 2026.

Profit growth outpaces sales

Roche said its 2025 diagnostics division and pharma portfolio both contributed to the year, but the headline numbers show that earnings quality mattered more than revenue direction. Core EPS of CHF 18.85 versus 2024 marked a 7% increase, which gives a firmer earnings anchor than the 2% constant-currency sales decline suggests.

Investors also tend to focus on the gap between reported and core figures in Roche’s annual reporting, because the group uses core numbers to describe operational performance. In that framework, CHF 11.1 billion of core operating profit is the key figure for assessing whether Roche is keeping operating leverage intact.

Pipeline still drives attention

Roche’s product mix remains central to the stock story because the group pairs a large pharmaceutical franchise with diagnostics, which gives the company multiple revenue drivers across cycles. That structure is why annual operating data matter even on days without a fresh company event: they define the base from which investors judge pipeline progress.

The most recent annual release also shows why margin remains a stronger read-through than simple sales growth. When core operating profit rises 7% while sales fall 2% at constant exchange rates, the market gets a clear signal that cost discipline and mix can offset a softer top line.

Pharma and diagnostics

Roche’s business is still anchored by its pharmaceutical portfolio and diagnostics platform, and those two segments are what make the company unusually sensitive to both drug launch momentum and testing demand. That mix matters more than generic sector language because it shapes how stable the earnings base can be through 2026.

The annual figures also help set expectations for the next reporting cycle. A sales base of CHF 60.5 billion and core operating profit of CHF 11.1 billion mean that even modest changes in pipeline performance, price, or diagnostic demand can move the earnings narrative materially.

Stock level and venue

Roche Holding stock is quoted on SIX Swiss Exchange, and the latest report-driven backdrop is best read against the company’s 2025 earnings base rather than against a speculative near-term catalyst. As a Swiss large-cap healthcare name, Roche tends to trade on profit durability, pipeline visibility, and margin protection.

Roche Holding fact box

• Company: Roche Holding AG
• ISIN: CH0012032048
• Ticker: SIX: RO
• Trading venue: SIX Swiss Exchange
• Sector / Industry: Healthcare / Pharmaceuticals
• Index membership: Swiss Market Index